Skip to Main Content Area

Funded Projects

Priority Projects
Small Projects
HICT Endorsed Trials

Priority Projects

Title	Lead PI
Biomarkers to Aid Treatment Decision Making in Early Stage Breast Cancer in Ontario	Mark Levine, McMaster University
Companion Circulating Tumour Cells Analysis to NCIC-CTG Clinical Trial	Jeremy Squire, Queen’s University
Circulating Tumor Cell analysis and characterization using novel microfiltration technology and FISH: A correlative biology companion study to the NCIC CTG Phase II Clinical Trial IND.205	Alison Allan, London Health Sciences Centre Research Inc.
Quantifying the Effect of Notch Inhibition on Tumour-Initiating Cells of Gamma-Secretase Inhibitor (RO4929097) in Advanced, Triple Negative Breast Cancer and Other Solid Tumours	Michael Reedijk, University Health Network
Multi-Institution Study of DCE CT Imaging Biomarkers of Tumours Microvasculature in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib	Masoom Haider, University Health Network
A Pilot Study of BOLD MRI and FLT-PET in Patients with Locally Advanced Breast Cancer Undergoing Neoadjuvant Chemotherapy	Mark Levine, McMaster University
Imaging with ¹¹¹In-Pertuzumab to predict response to Trastuzumab in HER2 Positive Metastatic Breast Cancer	Mark Levine, McMaster University
Genomics Path Study Feasibility Project	Lillian Siu, University Health Network
A Phase II Study of Sunitinib or Temsirolimus in Patients with Advanced Rare Tumours	Elizabeth Eisenhauer, Queen’s University

Back to top

Small Projects

Title	Lead PI, Institution	Award Total	Award Period
Translating the clinical utility of cancer microparticle enumeration and functional tumor imaging for combined prognosis of colorectal cancer	Barbara Fisher, Lawson Health Research Institute	$58,840	July 2012 - March 2013
Stem Cell Gene Expression Signatures in Clinical Pancreatic Cancer	Neesha Dhani, University Health Network	$61,219.34	July 2012 - March 2013
Correlation of Baseline Biomarker Levels with Clinical Outcomes and Response to Zactima in Bone Metastatic Breast Cancer Patients	Christina Addison, Ottawa Hospital Research Institute	$41,343.20	July 2012 - March 2013
Genomic profiling of circulating tumor cells (CTCs): a feasibility study	Alison Allan, Lawson Health Research Institute	$44,842.88	Jan 2012 – June 2012
Molecular Determinants of Outcome with mTOR Inhibition in Endometrial Cancer	Amit Oza, University Health Network	$68,789.63	October 2011 – March 2012
Companion Pharmacogenetic Study in the Ovarian Cancer ICON7 Trial	Helen Mackay, University Health Network	$100,000	October 2011 – March 2012
Evaluation of Correlative Biomarkers in Cervical Cancer Patients Treated with Temsirolimus, an Inhibitor of Mammalian Target of Rapamycin (mTOR)	Elizabeth Eisenhauer, Queen’s University	$55,140	October 2011 – March 2012
Identification and Validation of Plasma Biomarkers that Predict Response to Cediranib in Non-Small Cell Lung Cancer Patients	Christina Addison, Ottawa Hospital Research Institute	$70,696	October 2011 – March 2012
Companion Pharmacogenetic Study of BR.24	Geoffrey Liu, University Health Network	$88,140	October 2010 – March 2011
Drug Level Analysis Technologies for Personalized Cancer Therapy and High Impact Clinical Trial	Richard Kim, Lawson Health Research Institute	$102,097.50	October 2010 – March 2011
Integrated Molecular Profiling of Patient derived Tumour Xenograft Models for Preclinical Evaluation of Targeted Drugs and Biomarker Discoveries	Lillian Siu, University Health Network	$104,455	October 2010 – March 2011
Data Acquisition module for Real-Time Quantitative Ultrasound of neoadjuvant Chemotherapy Response Assessment	Gregory Czarnota, Sunnybrook Health Sciences Centre	$51,705	October 2010 – March 2011

Back to top

HICT Endorsed Trials

Title	Lead PI	TRT Site	Award Total	Award Period
Non-Invasive staging of prostate cancer: detection of circulating prostate microparticles using unique metastasis-specific antibody 1A5	Hon Leong	Lawson Health Research Institute	$5,544.00	October 2012 - September 2013
Prospective Identification of Risk Factors for Skeletal Related Events in Breast Cancer Patients Receiving Bisphosphonates for Bone Metastases. PROVIST 2	Mark Clemons	Ottawa Hospital Research Institute	$59,074.00	October 2012 - September 2013
ADMA as a Biomarker for Tumour Response, Overall Survival and Toxicities Related to Cediranib Treatment in Non-Small Cell Lung Cancer Patients in NCIC CTG BR.24	Glenwood Goss	Ottawa Hospital Research Institute	$55,490.00	October 2012 - September 2013
Exploratory analyses to evaluate potential biomarkers of resistance and response to single agent cabozatinib treatment in endometrial cancer – correlative studies on PHL-086 (pending)	Amit Oza	University Health Network	$50,026.21	October 2012 - September 2013
A Phase II Study of Ipilimumab in women with metastatic or recurrent HPV-related cervical carcinoma of either squamous cell or adenocarcinoma histologies	Amit Oza	University Health Network	$42,639.92	October 2012 - September 2013
A Phase II Single Arm Study Of AUY922 In patients with metastatic pancreatic adenocarcinoma who are resistant to first line chemotherapy	Malcolm Moore	University Health Network	$15,925	October 2011 – September 2012
A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer	Pamela Goodwin	University Health Network	$15,925	October 2011 – September 2012
A Phase II Study of AZD0530 as first line treatment in patients with metastatic or locally advanced gastric carcinoma	Helen MacKay	University Health Network	$9,403.33	October 2011 – September 2012
A Phase II Study of AZD0530 in patients with advanced, recurrent non-small cell lung cancer who have previously received platinum-based combination chemotherapy	Natasha Leighl	University Health Network	$9,403.33	October 2011 – September 2012
A Phase II Study of AZD0530 in Recurrent or Metastatic Soft Tissue Sarcoma	Margaret Von Mehren	University Health Network	$9,403.33	October 2011 – September 2012
A Phase II Study of GW786034 (Pazopanib) with or without Bicalutamide in Hormone Refractory Prostate Cancer	Amit Oza	University Health Network	$7,866.66	October 2011 – September 2012
The Role of VEGF-A Signaling in Maintenance of the Glomerular Filtration Barrier and Blood Pressure	Malcolm Moore	University Health Network	$7,866.66	October 2011 – September 2012
A phase I study of R04929097 in combination with gemcitabine in patients with advanced solid tumors	Phillipe Bedard	University Health Network	$7,866.66	October 2011 – September 2012
Randomized Phase III Study of Optimal Sequencing of Hormonal Therapy and Radiation in Patients with T1-T3 Prostate Cancer (OTT-01-01)	Shawn Malone	Ottawa Hospital Research Institute	$12,800	April 2011 – September 2011
A Multicentre Study Assessing 12-Weekly Intravenous Bisphosphonate Therapy in Women with Low Risk Bone Metastases from Breast Cancer using Bone Resorption Markers (ER 10-04, TRIUMPH)	Mark Clemons	Ottawa Hospital Research Institute	$59,124	April 2011 – September 2012
A Phase I Dose Finding Study of the Combination of High-Dose Statin Agent (Rosuvastatin) with Erlotinib in Patients with Advanced Solid Malignancies with a Focus on Squamous Cell Carcinomas and NSCLC (OTT-08-07)	Glen Goss	Ottawa Hospital Research Institute	$68,848	April 2011 – September 2012
A Phase I study of various administration schedules of RO4929097 with multiparameter assessment (biomarkers, pharmacokinetics, pharmacodynamics) in patients with advanced solid tumours	Sebastien Hotte	McMaster University	$20,305	October 2011 – September 2012
Randomised Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High Risk, Clinically Localized Prostate Cancer	Joseph Chin	Lawson Health Research Institute	$30,360	October 2011 - September 2012

Back to top